High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

Abstract Options for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after brentuximab vedotin (Bv) and autologous stem cell transplantation (ASCT) are limited. Immune checkpoint inhibitors (ICI) are active in this population but rarely induce complete response (CR). Ten...

Full description

Bibliographic Details
Main Authors: Lorenzo Falchi, Ahmed Sawas, Changchun Deng, Jennifer E. Amengual, Donald S. Colbourn, Emily A. Lichtenstein, Karen A. Khan, Lawrence H. Schwartz, Owen A. O’Connor
Format: Article
Language:English
Published: BMC 2016-11-01
Series:Journal of Hematology & Oncology
Subjects:
Hodgkin lymphoma
Pembrolizumab
Nivolumab
Azacitidine
Epigenetic therapy
Online Access:http://link.springer.com/article/10.1186/s13045-016-0363-1

Internet

http://link.springer.com/article/10.1186/s13045-016-0363-1

Similar Items